SUNRISE, FL--(Marketwire - Mar 12, 2013) - Bioheart Inc. (
Bioheart's president and CEO, Mike Tomas, said, "Bioheart is honored to have Kristin Comella leading our exciting platform of regenerative medicine products. Her dedication and accomplishments in the field are justifiably recognized by her peers."
About Bioheart, Inc.
Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.
About Stemlogix, LLC
Stemlogix high quality stem cell therapy and other regenerative medicine therapies are impacting the lives of cats, dogs and horses around the U.S. and in other countries. The company has developed a scientifically validated method for harvesting stem cells from both fat tissue and bone marrow for therapeutic use. The Stemlogix stem cell isolation processes provide for consistent cellular products that are compliant with current regulatory guidelines. Stemlogix has a highly experienced management team with over 20 years combined experience in developing multiple stem cell therapeutics for both human and animal use. In all of its products and services, Stemlogix aims to provide the best cutting-edge regenerative medical solutions, and seeks to provide companion animals and horses with renewed health and vitality. The company has partnered with Butler Schein Animal Health™, the leading companion animal health distribution company in the U.S., who are demonstrating the ease and effectiveness of the Stemlogix regenerative medicine treatments to veterinarians nationwide. To learn more about Stemlogix, LLC and its wide range of innovative regenerative medicine products please visit www.stemlogix.com, send an email to firstname.lastname@example.org or contact your local Butler Schein Animal Health™ representative.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2011, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.